You are here: Home » Current Affairs » Coronavirus » News
Health budget: Delhi, Mumbai spent more on tertiary than primary healthcare
Business Standard

Health ministry not to use Itolizumab in clinical protocols for Covid-19

The permission to market the drug was granted for the treatment of cytokine release syndrome in moderate' to severe' Acute Respiratory Distress Syndrome patients due to Covid-19

Topics
Coronavirus

Press Trust of India  |  New Delhi 



medicine
Biocon, has been manufacturing and marketing Itolizumab under brand name ALZUMAb

The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Sun, July 26 2020. 17:47 IST

RECOMMENDED FOR YOU